Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
NCT00466986
Completed
The purpose of this study is to determine if the combination of Abraxane and Carboplatin together will improve the chances of controlling recurrent ovarian/fallopian tube/peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
10/07/2011
Locations: Southeastern Gynecologic Oncology, Atlanta, Georgia
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Register for Updates
A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes
NCT00277043
Completed
The purpose of this study are to determine whether a test dose program for taxanes will reduce the rate and/or severity of hypersensitivity reactions (HSR); and to determine whether a test dose program for taxanes will result in cost reduction due to decreased drug wastage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2011
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Supportive, Ill-defined Sites
Register for Updates
Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy
NCT00505492
Terminated
Primary Objectives: 1. To test whether the addition of chemotherapy to radiotherapy improves the progression-free survival for patients with stage I, II and IIIa malignant mixed mesodermal tumor (MMMT) of the uterus. 2. To determine the acute and late toxicity profiles associated with this treatment regimen. 3. To describe the effect of this treatment regimen on the patient's quality of life.
Gender:
FEMALE
Ages:
All
Trial Updated:
09/13/2011
Locations: UT MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Uterine Neoplasms
Register for Updates
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
NCT00050167
Completed
Primary Objectives: * Determine the impact of each regimen on the disease free and overall survival of patients with operable breast cancer. * Determine the ability of docetaxel/capecitabine to downstage primary breast cancer when administered in the neoadjuvant setting when compared with weekly paclitaxel. * Determine the ability of each regimen to enhance breast conservation therapy when administered in the neoadjuvant setting. (See protocol text for additional objectives and details).
Gender:
FEMALE
Ages:
All
Trial Updated:
08/25/2011
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
NCT00165035
Completed
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent) in the treatment of single-vessel (one blood vessel) and multi-vessel (two or three blood vessels) coronary artery disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2011
Locations: Duke University Medical Center, Durham, North Carolina +1 locations
Conditions: Coronary Disease
Register for Updates
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
NCT00080418
Completed
The purpose of this study is to determine the highest dose of Liposome Entrapped Paclitaxel Easy to Use formulation (LEP-ETU) that can be safely administered by an intravenous infusion to patients with advanced cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2011
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida +2 locations
Conditions: Neoplasm
Register for Updates
Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer
NCT00100139
Completed
In this study, Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) is being compared to Taxol® to examine whether the paclitaxel in these 2 formulations undergoes similar processing by the body. Safety and tolerability of LEP-ETU and Taxol will also be assessed. In this study, each patient will receive one intravenous infusion of LEP-ETU or Taxol, followed 3 weeks later by an infusion of the other drug, at the same dose and infusion duration. Multiple blood samples will be taken for analysis bef... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2011
Locations: Cancer Institute of New Jersey - University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey +5 locations
Conditions: Neoplasm
Register for Updates
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy
NCT00803556
Completed
To determine the Maximally Tolerable Dose (MTD) of KOS-1022 when administered weekly in combination with trastuzumab or in combination with trastuzumab and paclitaxel to patients with advanced solid tumor malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2011
Locations: Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana +1 locations
Conditions: Solid Tumor, Breast Cancer
Register for Updates
ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer
NCT00110084
Completed
RATIONALE: Drugs used in chemotherapy, such as ABI-007(Nab-Paclitaxel((Nanoparticle Albumin Bound)-Paclitaxel)) and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving ABI-007 together with gemcitabine works in treating women with metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/31/2011
Locations: Mobile Infirmary Medical Center, Mobile, Alabama +200 locations
Conditions: Breast Cancer
Register for Updates
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
NCT00343291
Completed
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2011
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decatur, Alabama +42 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
NCT00667641
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel together with bortezomib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of paclitaxel and bortezomib in treating patients with metastatic or unresec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2011
Locations: Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey
Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer
NCT00317200
Completed
Improvements in therapy for relapsed SCLC are much needed. Paclitaxel has been previously tested and found to have significant single agent activity in relapsed SCLC, including in refractory patients. Angiogenesis plays an important role in SCLC, increased VEGF levels are associated with worse outcomes. Bevacizumab, a monoclonal antibody to VEGF, increase response rates and survival when combined with chemotherapy agents compared with the chemotherapy agent alone in NSCLC, breast cancer, and col... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2011
Locations: Highlands Oncology Group, Springdale, Arkansas +16 locations
Conditions: Small Cell Lung Cancer
Register for Updates